San Diego-primarily based Viking Therapeutics marked alone as a serious competitor while in the weight loss drug market place in February after revealing promising details from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the comp